⇚ Regimen TIBSOVO® - for Acute Myeloid Leukemia Medical Name TIBSOVO® (Ivosidenib) for Acute Myeloid Leukemia (AML) with a susceptible IDH1 mutation Cycles Given N/A Delivery Phases N/A Special Instructions Patients without IDH1 mutations at diagnosis should be retested at relapse because a mutation in IDH1 may emerge during treatment and at relapse. Monitor closely for symptoms of differentiation syndrome, QTc interval prolongation, anemia and electrolyte abnormalities. Treatment continued until disease progression or unacceptable toxicity. References DiNardo CD, et al. NEJM 2018 - VIEW External References http://www.nejm.org/doi/10.1056/NEJMoa1716984 - VIEW http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-first-line-treatment-aml-idh1-mutation - VIEW Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration TIBSOVO® (Ivosidenib) PO 500 mg Daily N/A N/A N/A N/A